Insight

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel from/X

Jun 28, 2024, 13:48

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel shared on X:

“Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24.

NEST clinical trial, 20 MSS, 3 MSI,
pMSS: 50% cPCR rate,
Really active in MSI and MSS CRC.”

Source: Arndt Vogel/X

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.

Agenus Arndt Vogel Balstilimab BOT/BAL BOT/BAL immunotherapy botensilimab cancer colorectal cancer Dhan Chand ESMO ESMOGI24 European Society for Medical Oncology Garo Armen Hannover Medical School Jennifer Buell Mehraneh Jafari Metastatic colorectal cancer MSS CRC NEST trial OncoDaily Oncology Pashtoon Kasi Steven O'Day

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage